Pharmacogenomics: The genomics of drug response

Yeast

Volumn 17, Issue 1, 2000, Pages 16-21

  March, Ruth ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Adverse events; Drug response; Personalized medicine; Pharmacogenetics; Pharmacogenomics; Toxicogcnomics

Indexed keywords

EID: 33748428120     PISSN: 0749503X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0061(200004)17:1<16::aid-yea6>3.0.co;2-e     Document Type: Article

References (41)

1. A receptor gene and response to clozapine. Mol Psychiatry 3: 61-66.
2. Bond C, LaForge KS, Tian M, et al 1998. Single-nucleotide polymorphism in the human μ opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95: 9608-9613.
3. Bruss M, Bonisch H, Buhlen M, Nothen MM, Propping P, Gothert M. 1999. Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5-HT1B receptor. Pharmacogenetics 9: 95-102.
4. Büscher R, Herrmann V, Insel PA. 1999. Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Trends Pharmacol Sci 20: 94-99.
5. Carson PEF, Flanagan CL, Ickes CE, Alving AS. 1956. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124: 484-485.
6. Collins F, Guyer MS, Charkravarti A. 1997. Variations on a theme: cataloging human DNA sequence variation. Science 278: 1580-1158.
7. Drazen J, Yandava CN, Dube L, et al. 1999. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet 22: 168-170.
8. Evans DAP, Manley KA, McKusick VA. 1960. Genetic control of isoniazid metabolism in man. Br Med J 2: 485-491.
9. Evans W, Relling MV. 1999. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 286: 487
10. Farr S, Dünn RT. 1999. 2nd Concise review: gene expression applied to toxicology. Toxicol Sci 50: 1-9.
11. Gonzalez F, Skoda RC, Kimura S, et al. 1988. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442-426.
12. Haas M, Yilmaz N, Schmidt A, et al. 1998. Angiotensinconverting enzyme gene polymorphism determines the anti-proteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press Res 21: 66-69.
13. Hodgson J. 1999. Analysts., firms pour cold water on SNP Consortium. Nature Biotechnol 17: 526
14. Hodgson J, Marshall A. 1998. Pharmacogenomics: will the regulators approve? Nature Biotechnol 16: 243-246.
15. Housman D, Ledley FD. 1998. Why pharmacogenomics? Why now? Nat Biotechnol 16: 492-493.
16. Hughes HB, Biehl JP, et al. 1954. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tubcrc 70: 266-273.
17. Kalow W. 1956. Familial incidence of low pseudocholinesterase level. Lancet 2: 576-577.
18. Kleyn P, Vesell ES. 1998. Genetic variation as a guide to drug development. Science 281: 1820-1821.
19. Kuivenhoven J, Jukema JW, Zwinderman AH, et al. 1998. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 338: 86-93.
20. Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279: 1200-1205.
21. Lennard LL, Lilleyman JS, Van Loon J, Weinshilboum RM. 1990. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336: 225-229.
22. Mahgoub A, Idle JR., Dring LG, Lancaster R, Smith RL. 1977. Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584-586.
23. Marshall A. 1998. Laying the foundations for personalized medicines. Nature Biotechnol 16: 954-957.
24. Marshall A. 1998. Getting the right drug into the right patient. Nature Biotechnol 15: 1249-1252.
25. Masood E. 1999. As consortium plans free SNP map of human genome. Nature 398: 545-546.
26. Meyer U, Zanger UM. 1997. Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann Rev Pharmacol Toxicol 37: 269-296.
27. Nakamura M, Zhang ZQ, Shan L, et al. 1997. Allelic variants of human calcitonin receptor in the Japanese population. Hum Genet 99: 38-41.
28. Nebert DW. 1997. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist?. Am J Hum Genet 60: 265
29. Nebert D, Ingelman-Sundberg M, Daly AK. 1999. Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metab Rev 31: 467-487.
30. Nuwaysir E, Bittner M, Trent J, Barrett JC, Afshari CA. 1999. Microarrays and toxicology: the advent of toxicogcnomics. Mol Carcinog 24: 153-159.
31. Poirier J, Delisle MC, Quirion R, et al. 1995. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 92: 12260-12264.
32. Pharmacogenomics Supplement. 1998. Nature Biotechnol. 16(10).
33. Rodi C, Bunch RT, Curtiss SW, et al. 1999. Revolution through genomics in investigative and discovery toxicology. Toxicol Pathol 27: 107-110.
34. Sadee W. 1999. Pharmacogenomics. Br Med J 319: 1286
35. Silverman E, In KH, Yandava C, Drazen JM. 1998. Pharmacogenetics of the 5-lipoxygenase pathway in asthma. Clin Exp Allergy 28 (suppl 5): 164-170.
36. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. 1998. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiat 3: 508-511.
37. Schmidt K. 1998. Just for you. New Scientist 14 November.
38. Spears B. 1999. Applying the science: we're only a step away. Presented at Symposium on Genetics in the Pharmaceutical Industry, San Francisco, CA.
39. Taboulet J, Frenkian M, Frendo JL, Feingold N, Jullienne A, de Vernejoul MC. 1998. Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. Hum Mol Genet 7: 2129-2133.
40. Weber WW. 1997. Pharmacogenetics. Oxford University Press: Oxford.
41. Weinshilboum R, Sladek SL. 1980. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32: 651-662.